RU2475249C1 - Agent for external therapy of chronic recurrent inflammatory dermatopathies - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: what is presented is the use of xenon in the form of an agent for external therapy of chronic recurrent inflammatory dermatopathies prepared by extra pure grade xenon saturation of a fatty base.

EFFECT: what is shown is considerable reduction of an inflammatory reaction on the second therapeutic day in such polygenic chronic inflammatory diseases, as psoriasis, atopic dermatitis, acne, acne rosacea, eczema.

4 ex

Description

The invention relates to practical medicine and can be used in dermatology for external therapy of chronic inflammatory skin diseases such as psoriasis, atopic dermatitis, acne, rosacea, eczema.

Psoriasis is one of the most common skin diseases. According to statistics, from 1 to 8% of the world's population suffers from this pathology. Cases of severe forms that are difficult to treat and lead to disability of patients with frequent and prolonged relapses are becoming more frequent (1).

Atopic dermatitis (AD) is one of the most common diseases that occurs in all countries, in people of both sexes and in different age groups. According to numerous authors, the incidence varies from 6 to 20% per 1000 population. The incidence of blood pressure among residents of megacities is higher than among residents of rural areas. In children, blood pressure occurs in 1-4% of cases (up to 10-15%) among the entire population, while in adults it occurs in 0.2-0.5% of cases (2).

Acne is the most common chronic recurrent disease of the sebaceous glands and hair follicles, affecting up to 85% of people aged 12 to 25 years and 11% of people over 25 years old (3).

Eczema is a ubiquitous, recurring skin disease that occurs at any age. Eczema accounts for 30-40% of all skin diseases (4).

Rosacea is a chronic, recurring disease, usually of the skin of the face, having a polyetiological nature. Among dermatological diagnoses, it is about 5% (5).

The arsenal of drugs used for external treatment of chronic recurrent inflammatory skin diseases includes such common ointments as sulfur ointment, papaverine cream, Unna cream, zinc ointment, etc.

Despite the successes achieved by domestic and foreign dermatology, the incidence of dermatoses remains very high. Currently, there is an increase in the number of patients resistant to traditional external therapy, and many dosage forms cannot be used due to drug intolerance and the formation of side effects (6).

The objective of the invention is to expand the arsenal of means of external therapy for skin diseases, reducing treatment time.

The problem is achieved in that xenon is used as an external treatment for chronic relapsing inflammatory skin diseases.

The use of xenon as an inhaled anesthetic agent with analgesic, antispasmodic, cardiotonic, neuroprotective, anti-stress, antihypoxic, immunostimulating, anti-inflammatory, anabolic, neurohumoral, and vasoplegic properties is known (7).

According to the order of the Ministry of Health of the Russian Federation No. 363 of 10/10/1999, the Russian Pharmacological Committee authorized the use of xenon in medical practice.

In the analyzed literature, the use of xenon in clinical practice as a means for the external treatment of chronic recurrent inflammatory skin diseases was not found. Thus, in the claimed invention, xenon exhibits its new property, which leads to the achievement of a new technical result, and the proposed drug has no adequate analogues, does not explicitly follow from the prior art and is not obvious to a specialist.

The present invention can be used in medical practice as a new treatment for chronic recurrent inflammatory skin diseases, reducing the treatment time for skin diseases.

Based on the foregoing, the present invention should be considered relevant to the conditions of patentability "Novelty", "Inventive step", "Industrial applicability".

The invention will be clear from the following description.

The proposed tool for external therapy is obtained by saturating the fat base with xenon of high purity ("Xenon OCH", TU 2114-003-39791733-2002) by sparging. Sparging is carried out through fine-pore glass bubblers in 1000 ml flasks, in a volume of xenon inert gas equal to the volume of the fat base until an equilibrium concentration is reached. The sparging process is carried out at a temperature of 35-40 ° C for 5-10 minutes with continuous stirring. The determination of the gas content in the means for external therapy is carried out using the method of gas-liquid chromatography.

The treatment is carried out by prescribing xenon to the affected skin in the form of an external therapy at the dose necessary to apply a thin layer adequately to the lesion 1-2 times a day in the morning and evening, for the treatment of various chronic recurrent inflammatory skin diseases (psoriasis, acne, atopic dermatitis, rosacea, eczema).

Example 1. Patient M., 56 years old. Ds: Psoriasis vulgar, numular-plaque, common, mixed type, progressive stage, PASI = 28, 2 points.

External therapy consists in applying Unna cream to the left half of the body. An external therapy agent in the form of a cream enriched with xenon is applied to the right side of the body. The basis of the cream is obtained according to the following recipe:

Rp: Lanolini

Ol. Persicorum

Aq. destil. aa 50.0

M.D.S. The basis of xenon sparging cream.

External therapy is applied in equal amounts to the affected areas 2 times a day, morning and evening, together with the use of general therapy.

The patient undergoes thermometry of the pathological foci, as well as an assessment of the clinical picture by the index of the area of psoriatic lesions and the severity of the PASI process.

- On the 2nd day of external therapy: on the right PASI = 21.4 points, on the left PASI = 26.2 points; thermometry indicators decreased to a greater extent on the right by 0.53 ° C, on the left by 0.31 ° C.

- On the 7th day: on the right PASI = 9.2 points, on the left PASI = 18.6 points. Due to the fact that the severity of the clinical picture according to the PASI index on the left decreased by 34% and on the right by 67.4%, which is 1.98 times more, as well as thermometry indicators indicating a significant decrease in the inflammatory reaction on the right, the decision was made as local therapy to use an agent enriched in xenon.

Thermometry (Δt ° C) * day Right 1/2 Left 1/2 one 35.72 35.59 2 35.19 35.28 7 32.96 34.94 16 30.93 31.05

* - thermometry is performed on the largest psoriatic plaques of the legs. Measurements are performed at 11 points of the pathological foci using the CEM Thermo Diagnostics apparatus and the further calculation of Δt ° C.

- When discharged for 16 days, PASI is 3.6 points, so PASI decreased by 87.2%, which meets the criteria for significant improvement.

Example 2. Patient S., 28 years old. Ds: Atopic dermatitis, erythematic-lichenoid form. SCORAD score 49 points. Sick from 3 years, notes exacerbation in the spring-autumn period.

External therapy consists in applying 5% papaverine cream to the left side of the body. An external therapy agent in the form of a cream enriched with xenon is applied to the right side of the body. The basis of the cream is obtained according to the following recipe:

Rp: Lanolini

Ol. Persicorum

Aq. destil. aa 50.0

M.D.S. The basis of xenon sparging cream.

External therapy is applied in equal amounts to the affected areas 2 times a day, morning and evening, together with the use of general therapy.

The patient undergoes thermometry of pathological foci, as well as an assessment of the clinical picture by the SCORAD index of severity of atopic dermatitis.

- On the 2nd day of therapy: on the right SCORAD = 40.5 points, on the left SCORAD = 46 points; thermometry indicators decreased to a greater extent on the right by 0.69 ° C, on the left by 0.21 ° C.

- On the 7th day of therapy: on the right SCORAD = 27.1 points, on the left SCORAD = 36.7 points. Due to the fact that the score on the SCORAD index on the left decreased by 25.1%, and on the right by 44.7%, which is 1.78 times more, and thermometry indicators, indicating a decrease in inflammatory activity on the right by 2 ° C, and on the left by 0.65 ° C, which is 1.35 ° C more, it was decided to use an agent enriched in xenon as local therapy.

Thermometry (Δt °) * day Right 1/2 Left 1/2 one 35.69 35.7 2 35 35.49 7 33.69 35.05 eighteen 32.22 32,42 * - thermometry is performed on pathological foci of the flexion surface of the elbow joints. Measurements are performed at 11 points of the pathological foci using the CEM Thermo Diagnostics apparatus and the further calculation of Δt ° C.

When discharged on day 18, the clinical picture score on the SCORAD index is 8.6 points, i.e. SCORAD decreased by 82%, which meets the criteria for significant improvement.

Example 3. Patient G., 30 years old. Ds: Dyshidrotic eczema of the hands. DASI score = 36 points, which meets the criterion of severe dyshidrotic eczema.

External therapy consists in applying zinc ointment to the affected skin of the left hand. An external therapy agent in the form of an ointment enriched with xenon is applied to the right hand. The basis of the ointment is obtained according to the following recipe:

Rp .: Lanolini anhydrici

Vaselini aa 15.0

M.f. ung.

D.S. The basis of the ointment for bubbling xenon.

External therapy is applied in equal amounts to the affected areas 2 times a day, morning and evening, together with the use of general therapy.

The patient undergoes thermometry of the pathological foci, as well as an assessment of the clinical picture by the index of the lesion area and the severity of the disease with DASI dyshidrotic eczema.

- On the 2nd day of therapy: on the right, DASI = 24 points, on the left, DASI = 36 points; thermometry indices decreased to a greater extent on the right by 1.38 ° С, on the left by 0.19 ° С.

- On the 7th day of therapy: on the right, DASI = 6 points, on the left, DASI = 12 points. Due to the fact that the DASI score on the right decreased by 83.3%, on the left by 66.7%, which is 1.25 times more, and thermometry on the right indicates a decrease in inflammatory activity by 2.57 ° C, and on the left by 1.05 ° C, which is 1.52 ° C higher, it was decided to use an agent in the form of an ointment enriched with xenon as an external therapy.

Thermometry (Δt °) * day Right 1/2 Left 1/2 0 36.03 35.95 2 34.65 35.76 7 33.46 34.9 21 31.37 31.35 * - thermometry is performed on pathological foci of the flexion surface of the elbow joints. Measurements are performed at 11 points of the pathological foci using the CEM Thermo Diagnostics apparatus and the further calculation of Δt ° C.

When discharged for 21 days, the assessment of the clinical picture by the DASI index is 1 point, i.e. DASI decreased by 97%, which meets the criteria for significant improvement.

Example 4. Patient E., 20 years old. Ds: Acne, papulopustular form, severe. Sick for 6 years. Previously used topical retinoids, antibiotics, benzoyl peroxide. There was no significant improvement.

External therapy consists in applying 10% sulfuric ointment to the left half of the skin of the face, neck, back, chest. An external therapy agent in the form of an ointment enriched with xenon is applied to the right half of the skin of these areas. The basis of the ointment is obtained according to the following recipe:

Rp .: Lanolini anhydrici

Vaselini aa 15.0

M.f. ung.

D.S. The basis of the ointment for bubbling xenon.

External therapy is applied in equal amounts to the affected areas 2 times a day, morning and evening, together with the use of general therapy.

The patient undergoes thermometry of morphological elements, as well as an assessment of the clinical picture.

- On the 2nd day of therapy: on the right, the papules sagged significantly, turned pale; no dynamics are marked on the left.

- On the 7th day: on the right - morphological elements of an inflammatory nature resolved to stagnant spots of a pale pink color, there are no fresh rashes, on the left - isolated papules slightly settled, hyperemia of the elements persists, 2 fresh papular elements on the skin appeared in the projection of the lower jaw; thermometric indicators indicate a decrease in inflammatory activity on the skin on the right by 3.9 ° C, on the left by 0.7 ° C, which is 3.21 ° C more, and therefore it was decided to use an agent in the form of an ointment as an external therapy, enriched with xenon.

Thermometry (Δt °) * day Right 1/2 Left 1/2 0 35.27 35.13 2 34.15 34.83 7 32.88 34.43

* - Thermometry is carried out on papular elements of the skin of the face. Measurements are performed at 6 points on the right half of the face and at 6 points on the left half using the CEM Thermo Diagnostics apparatus and then calculating Δt ° C.

When discharged for 30 days, there is a decrease in inflammatory elements by 50%, which meets the criteria for clinical improvement. After 6 months of therapy, which is based on xenon in the form of an ointment, the clinical picture regressed more than 75%, which meets the criteria for significant improvement.

When evaluating the effectiveness of treatment of patients with acne with an external therapy agent enriched with xenon, according to the proposed method, the following results were obtained:

- in 25.7% of patients there is a significant decrease in the inflammatory response on the 2nd day of xenon administration in the form of an ointment;

- 74.3% on the 7th day there is a resolution of inflammatory elements;

- 83% after 14 days of use, fresh elements do not appear.

The present invention was applied in 26 patients, and the technical result obtained is to reduce the treatment time.

Information sources

1. Milevskaya S.G., Pesterev P.N. Psoriatic arthritis. - 1996

2. Volkova E.N. Atopic dermatitis. Therapist. - 2006 - No. 9.

3. Adaskevich V.P. Acne is vulgar and pink. - 2005

4. Skripkin Yu.K. Skin and sexually transmitted diseases. - 1995

5. Potekaev N.N. Acne and rosacea. - 2007

6. Chess master I.Ya., Dovzhansky S.I. Treatment of skin diseases. - 1990

7. Suslov NI, Shpisman MN, Potapov V.N. The use of xenon in medicine. - 2009

Claims (1)

The use of xenon in the form of an agent for the external treatment of chronic recurrent inflammatory skin diseases, obtained by saturating the fat base with high purity xenon.